Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
NCT03705858
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Due to difficulty in finalizing the contract
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Ac-Lintuzumab
Sponsor
Joseph Jurcic